Latest News

In honor of National Cancer Research Month, Dr. Jeffrey Townsend shares why his research is focused on cancer.

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer, according to a new Yale study.

The American Association for the Advancement of Science has elected eight Yale faculty members as part of its latest class of fellows.

Test positivity, emergency room visits, hospitalizations, and deaths due to COVID are increasing as we enter the new year. YSPH Professor Jeffrey Townsend warns, "It’s still dangerous."

According to Yale, the study findings “have significant implications for public health policy and individual decision-making.”

A one-size-fits-all approach for scheduling COVID-19 booster shots may not be the most effective, according to a new study by researchers at the Yale School of Public Health and University of North Carolina at Charlotte. The best time for people to get a booster actually varies based on where they live and their personal infection history.

A retrospective cohort study by Yale Cancer Center researchers of nearly 200 patients with melanoma who died after receiving treatment with immunotherapy highlights a need to improve outcomes for patients who progress or relapse after the treatment.

Jeffrey P. Townsend, PhD, Elihu Professor of Biostatistics and professor of Ecology and Evolutionary Biology, co-leader, Genomics, Genetics, & Epigenetics Research Program, Yale School of Public Health, discusses analyses of driver mutations in prostate cancer driver using early neoplasm tissue samples to help characterize the molecular and genetic progress of the disease.

“When the study launched, even with operable pancreatic cancers, 90% of patients were still relapsing and dying from their cancer eventually,” said Dr. Michael Cecchini, the first author of the study and the co-director of the colorectal program at the Center for Gastrointestinal Cancers at Smilow Cancer Hospital and YCC. “We sought to move chemotherapy up in their treatment regimen and give it before surgery to see if we could improve the outcome for our patients.”